Part VI: Summary of the risk management plan

Summary of risk management plan for Carboplatin 10 mg/ml (Carboplatin) concentrate for solution for infusion

This is a summary of the risk management plan (RMP) for carboplatin (10 mg/ml) concentrate for solution for infusion. The RMP details important risks of carboplatin (10 mg/ml) concentrate for solution for infusion, how these risks can be minimised, and how more information will be obtained about carboplatin (10 mg/ml) concentrate for solution for infusion's risks and uncertainties (missing information).

Carboplatin (10 mg/ml) concentrate for solution for infusion's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how carboplatin (10 mg/ml) concentrate for solution for infusion should be used.

Important new concerns or changes to the current ones will be included in updates of carboplatin (10 mg/ml) concentrate for solution for infusion's RMP.

I. The medicine and what it is used for

It is an antineoplastic agent, platinum compounds. It is indicated for the treatment of

1. Advanced ovarian carcinoma of epithelial origin in:
    - First line therapy
    - Second line therapy, after other treatments have failed.
2. Small cell carcinoma of the lung.

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of carboplatin (10 mg/ml) concentrate for solution for infusion, together with measures to minimise such risks and the proposed studies for learning more about carboplatin (10 mg/ml) concentrate for solution for infusion's risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size - the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status - the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute routine risk minimisation measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed, including PSUR assessment and signal management activity, so that immediate action can be taken as necessary. These measures constitute routine pharmacovigilance activities.

If important information that may affect the safe use of carboplatin (10 mg/ml) concentrate for solution for infusion is not yet available, it is listed under 'missing information' below.

II.A List of important risks and missing information

Important risks of carboplatin (10 mg/ml) concentrate for solution for infusion are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely taken. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of d carboplatin (10 mg/ml) concentrate for solution for infusion. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine);

Important identified risk (s)	• Hypersensitivity and anaphylaxis • Myelosuppression • Use in pre-existing severe renal impairment and

	nephrotoxity • Concurrent therapy with nephrotoxic drugs or ototoxic drugs • Neurotoxicity • Severe hepatic dysfunction including acute liver necrosis and Venoocclusive liver disease • Ototoxicity • Tumour lysis syndrome • Haemolytic anaemia
Important potential risk (s)	• Secondary malignancies • Overdose
Missing information	• Use in Pediatric population

II.B Summary of important risks

The safety information in the proposed Product Information is aligned to the reference medicinal product.

II.C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of carboplatin (10 mg/ml) concentrate for solution for infusion.

II.C.2 Other studies in post-authorisation development plan

There are no studies required for carboplatin (10 mg/ml) concentrate for solution for infusion.